Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inactivated convalescent plasma in hospitalized COVID-19 patients
NCT04385186Phase 2Unknown
- Sponsor
- AABB Foundation
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inactivated convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AABB Foundation. Primary endpoint: Mortality reduction in CoViD-19 patients at 28 days. Status: unknown.
02
Drugs
inactivated convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04385186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385186.